NextCure, Inc.
NextCure, Inc. (NXTC): 7 pipeline candidates · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.5 months
D/E 0.42 · 45% dilution
Lead: Phase 1/Phase 2
7 candidates
N/A
N/A
A transparent, data-derived signal for NextCure, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.9M
Cash
$15.2M
Quarterly Burn
$13.4M
Runway
4.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$9.8M
| Holder | Shares | Value |
|---|---|---|
| affinity asset advisors, llc | 241,826 | $2.6M |
| silverarc capital management, llc | 176,057 | $1.9M |
| vanguard capital management llc | 160,473 | $1.7M |
| boothbay fund management, llc | 69,617 | $744K |
| renaissance technologies llc | 60,534 | $647K |
| woodline partners lp | 54,996 | $587K |
| verdad advisers, lp | 42,955 | $459K |
| geode capital management, llc | 31,092 | $327K |
| blackrock, inc. | 27,793 | $297K |
| cardiff park advisors, llc | 21,833 | $233K |
Showing top 10 of 19 institutional holders of NextCure, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NextCure, Inc.'s pipeline?
NextCure, Inc. (NXTC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NextCure, Inc.'s lead drug candidate?
NextCure, Inc.'s most advanced tracked candidate is lncb74 (Phase 1) for Ovarian Cancer.
What is NextCure, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NextCure, Inc. has approximately 4.5 months of cash runway.
What is NextCure, Inc.'s market capitalization?
NextCure, Inc.'s market capitalization is approximately $7.9M.
Who is the CEO of NextCure, Inc.?
Mr. Michael S. Richman MSBA is the chief executive officer of NextCure, Inc. (NXTC).
Get the full picture on NextCure, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.